Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05530655
EARLY_PHASE1

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Sponsor: University of Rochester

View on ClinicalTrials.gov

Summary

This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.

Official title: A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-02-20

Completion Date

2028-01-01

Last Updated

2026-01-13

Healthy Volunteers

No

Interventions

DRUG

Lisinopril Tablets

This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.

Locations (1)

Wilmot Cancer Institute

Rochester, New York, United States